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Dementia is responsible for the greatest burden of neurodegenerative diseases, with 
Alzheimer’s Disease (AD) representing approximately 60-70% of dementia cases1. To 
organize optimal individual care for these patients and to predict the disease course, a 
correct diagnosis is essential.  Therefore, a standard clinical work up normally  includes  
a clinical evaluation, neuropsychological tests and imaging of the brain is performed.  
Clinical diagnosis is established by multidisciplinary team consensus according to the 
NIA-AA criteria2. Since the development of in vivo biomarkers, information about the 
pathophysiological process is becoming more important to diagnose AD3. 
Histopathological hallmarks of AD are deposits of extracellular Amyloid (Aβ) protein 
and hyper phosphorylated Tau proteins, aggregated in intracellular neurofibrillary 
tangles4,5. Valid diagnostic biomarkers are linked to neuropathology and detect the 
disease early in its course and distinguish it from other neurodegenerative diseases6. 
This thesis focus on Cerebrospinal  fluid (CSF) compounds- and nuclear molecular 
imaging Positron Emission Tomography (PET)  tracer biomarkers to diagnose and stage 
the different types of dementia.   
 
Summary of main findings 
Part 1. 
In the first part of the thesis, CSF biomarkers are described and their potential to 
discriminate AD and different types of dementia. The AD-CSF biomarker profile is 
characterized by decreased  concentration of CSF Aβ  and increased concentration of CSF 
Tau and P-Tau7. In chapter 2, the perspectives of the established CSF biomarkers and 
potential new biomarkers in dementia are discussed, with an update of the past and the 
present. In chapter 3, CSF biomarkers Aβ1-42 , Tau and P-Tau were investigated in a 
broad population visiting a memory clinic. Baseline CSF was collected from 512 AD 
patients and 272 patients with other types of dementia, 135 patients with a psychiatric 
disorder and 275 patients with only subjective memory complaints (SMC). Autopsy was 
obtained in a subgroup of patients in who neuropathological diagnosis was obtained and 
the concordance with clinical diagnosis was 85%, while CSF markers reflected 
neuropathology in 94%. Older patients are more likely to have a CSF AD biomarker 
profile. We found overlap in CSF biomarker AD profile with other types of dementia, 
especially in patients with Lewy Body Dementia (DLB, 47% ), Corticobasal degeneration 
(CBD, 38% ), and 30% in both Frontotemporal dementia (FTD) and vascular dementia 
(VaD). Normal CSF biomarker profiles were found in 91% of patients with a psychiatric 
disorder and in 88% of patients with subjective memory complaints.  The conclusion 
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was, that the AD-CSF biomarkers are useful to diagnose AD, but to differentiate AD from 
other types of dementia, more specific CSF biomarkers  are needed. In chapter 4, CSF α-
Synuclein was assessed as a biomarker to differentiate DLB and Parkinson Disease (PD), 
which represent two Parkinson syndromes with α-Synucleinopathy as pathologic 
hallmark, from  AD. We included 35 patients with DLB, 63 AD patients, 18 PD patients 
and 34 patients with SMC. In our subjects, the CSF α-Synuclein levels could not 
differentiate between the diagnostic groups (p = 0.16). On the other hand, in DLB 
patients, linear regression analyses of CSF biomarkers showed that lower α-Synuclein 
was related to lower MMSE and fluency (p < 0.05) and thus related to impaired (worse) 
cognitive performance. Elevation of the AD-CSF biomarker levels P-Tau and Tau, 
enabled  differentiation between  AD and DLB patients (p < 0.05), although various DLB 
patients had also a CSF AD profile compared to patients with subjective memory 
complaints or PD(p < 0.05). Therefore,  we concluded based on this investigation that α-
Synuclein CSF biomarker was  not useful  to differentiate DLB or PD from AD or 
subjective memory complaints and other biomarkers are needed.  
Part 2 
In the second part of the thesis, the diagnostic potential of positron emission 
tomography (PET) biomarkers in dementia was investigated. Molecular imaging 
techniques, such as amyloid PET ligands, localize and quantify amyloid depositions8.  
[11C]Pittsburgh Compound-B ([11C] (PiB) is an accurate amyloid ligand, although the 
short half-life of [11C] (20 min), limits its use to centres with a cyclotron and a 
specialised radiochemistry department. [18F]FDG is a glucose metabolism tracer and as 
such is a topographic marker for synaptic dysfunction and can thus be applied in a wider 
field of neurodegeneration than AD9. Chapter 5 does not contain research data but gives 
an overview of functional imaging and PET biomarkers for FTD, a major cause of young 
onset dementia. FTD is a heterogeneous  syndrome, with different clinical subtypes. 
Neuropathological characteristics of FTD can be divided in tauopathy (FTD-TAU), 
ubiquitin pathology (FTD-U or FTD-TDP) or can be associated with Fused in Sarcoma 
(FUS) protein accumulation (FTD-FUS). Almost half of FTD cases are familial and genetic 
heterogeneity is reflected by the identification of mutations in causative genes. 
Diagnostic criteria have modest sensitivity and it is challenging to differentiate FTD from 
other types of dementia, especially AD. [18F] FDG-PET improves early diagnosis and 
differentiation of FTD and AD particularly because frontotemporal hypometabolism 
correlates with the clinical symptoms. Nuclear imaging techniques may also be helpful in 
the detection of amyloid markers or deficits of the serotonergic, noradrenergic or 
cholinergic neurotransmitter systems, depending on the degeneration of subcortical 
nuclei and thereby provide valuable insight in the pathophysiology of FTD. In addition, 
TAU PET scan is expected to have a role in the diagnosis of specific subtypes of FTD, but 
Tau tracers are not yet available in clinical practise10. In chapter 6 we identified a DLB-
related cerebral glucose metabolic covariance pattern(DLBRP) using a multivariate 
Scaled Subprofile Model and Principal Component Analysis (SSM PCA) analysis in 
[18F]FDG PET in 19 healthy controls (HC) and 19 DLB subjects in a Dutch cohort. The 
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DLBRP expression was subsequently validated in an independent Belgian cohort of 20 
HC and 37 DLB subjects. Altered regional FDG PET uptake in DLB is a supportive 
biomarker for Dementia with Lewy Bodies (DLB), although its diagnostic specificity is 
not yet clear. SSM PCA derived patterns have shown to be useful in tracking disease 
progression and differential diagnosis and have advantages over univariate techniques 
in multiple neurodegenerative diseases, including AD and PD. The DLBRP was 
characterized by relative hypometabolism in the occipital cortex (including the primary 
visual cortex), parietal cortex and lateral frontal cortex, covarying with relatively 
increased metabolism in the brainstem, cerebellum, putamen/pallidum, thalamus, and 
sensorimotor cortex. FDG standardized uptake value (SUV) in the occipital (visual) 
cortex was decreased in patients (p<0.001) and correlated with the DLBRP in the DLB 
subjects of the Dutch cohort, a correlation, however, which did not reach statistical 
significance in the Belgian cohort. These group differences were speculated to relate to 
the variance in clinical presence of visual hallucinations in the two cohorts and 
differences in underlying neuropathology. In this, a variable amount of ‘pure’ neocortical 
Lewy body pathology was considered11. We conclude that 18F-FDG-PET imaging, 
combined with semi-quantitative multivariate analysis techniques, such as SSM PCA, 
represents a reliable and valuable biomarker in DLB diagnosis. The clinical implication 
of this DLBRP to differentiate from other neurodegenerative disease pathology as in AD 
or PD, needs further investigation. In this respect, future molecular imaging studies 
targeting α-Synucleinopathy are expected to shed further insights into the pathogenesis 
of DLB and the relationship between different pathologies. Chapter 7 describes four out 
of 29 PIB-positive AD subjects selected from the Dual PET project, i.e. our study with 
combined 18F-FDG PET and 11C-PiB PET imaging, who exhibited reduced cerebellar FDG 
uptake associated with reduced uptake in the contralateral cerebral hemisphere. The 
patients were diagnosed according to the National Institute on Aging - Alzheimer 
Association (NIA-AA) criteria. PET has additional value on top of the standard diagnostic 
work-up in AD, especially in early disease or when prior diagnostic confidence is low12. 
A “classic” AD [18F] FDG-PET scan shows hypometabolism in the temporal-parietal 
association cortex, more variably also in the prefrontal cortex, but with a relative 
preservation of metabolism in the primary visual and sensorimotor cortex, striatum, and 
cerebellum13. Such prefrontal involvement was particularly the case in the described 
patients. The cerebellum is often used as a reference region in the analysis of PET brain 
scans14, because of the late stage cerebellar involvement in AD in post-mortem studies15. 
Although, [18F] FDG PET AD pattern can also predominantly show focal and lateralized 
hypometabolism and contralateral cerebellar hypometabolism can be observed, 
disputing the function as a reference region.  This is the first report describing in a small 
subset of subjects the phenomenon of crossed cerebellar diaschisis (CCD) in AD. CCD is 
the phenomenon of unilateral cerebellar hypometabolism as a remote effect of 
supratentorial dysfunction of the brain in the contralateral hemisphere.  The mechanism 
implies the involvement of the cortico-ponto-cerebellar fibers. The pathophysiology is 
thought to have a functional or reversible basis but can also reflect secondary 
morphologic change. We found a correlation and interaction between  Aβ deposition and 
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reduced glucose metabolism and a possible role of the bloodflow. We hypothesed that 
CCD  can be explained on a functional basis due to the non-amyloid neurodegenerative 
pathology in the contralateral (particularly left) hemisphere. In chapter 8 dual-tracer 
studies with 18F-FDG and 11C-PIB PET are used to assess respectively metabolism and 
cerebral amyloid-β deposition in AD. Regional cerebral metabolism and blood flow 
(rCBF) are closely coupled, both providing an index for neuronal function. The present 
study compared 11C-PIB-derived rCBF, estimated by the ratio of tracer influx in target 
regions relative to reference region (R1) and early-stage 11C-PIB uptake (ePIB), to FDG 
scans. By making this comparison we aimed to assess the use of R1 and ePIB as a 
surrogate for 18F-FDG. To that end, 15 11C-PIB positive (+) patients and 15 11C-PIB 
negative (-) subjects underwent both FDG and 11C-PIB PET. First, subjects were 
classified based on visual inspection of the 11C-PIB PET images. Then, discriminative 
performance (PIB+ versus PIB-) of rCBF methods were compared to normalized 
regional 18F-FDG uptake. Strong positive correlations were found between analyses, 
suggesting that the 11C-PIB-derived rCBF provides information that is closely related to 
what can be seen on 18F-FDG scans. Further studies are needed to validate the use of R1 
as an alternative for 18F-FDG studies in clinical applications. Chapter 9 describes the 
preliminary results of the ‘dual PET’ study, i.e. combined 11C-PiB and 18F-FDG PET scans 
in the clinical diagnosis of AD and other types of dementia. In this ongoing study, 89 
subjects were included, with a clinical diagnosis of MCI, probable AD, probable DLB, FTD 
and healthy controls. For this preliminary analysis, an image-driven approach was 
chosen to investigate the potential of ‘Dual PET’ scans in the different patient groups. To 
that end, a “blinded” expert made a visual judgment of the PET- scans, without 
knowledge of the clinical symptoms. At first, 11C-PiB PET scans were judged as amyloid 
positive (n=44) or negative (n=45); next 18F-FDG PET scans were assigned as (i) ‘classic’ 
AD pattern, (ii) non- or atypical AD pattern or (iii) a normal 18F-FDG PET  pattern. It 
appeared that the majority of subjects with a clinical diagnosis of AD (18 of 20 subjects) 
had both a positive [11C]PIB PET scan and a ‘classic AD’ [18F] FDG PET pattern. The non- 
or atypical AD [18F] FDG PET patterns associated with [11C] PIB-positive PET scans 
(18%) concerned subjects that clinically presented as an atypical AD; yielding a 
‘spectrum’ with other neurodegenerative dementias and are assembled in AD- 
syndromes, as corticobasal syndrome (CBS), primary progressive aphasia (PPA) and 
posterior cortical atrophy (PCA)16. In a minority of subjects (9 %) had normal [18F] FDG 
PET metabolism and a positive [11C] PIB PET scan, suggesting an early sign of disease17. 
In most of the [11C] PIB- PET negative scans, subjects were clinically diagnosed as FTD. 
In 35 % of [11C] PIB- PET negative subjects, the [18F] FDG PET pattern was classified as 
“classic AD”. The clinical diagnosis of these patients comprised DLB, FTD, other 
dementia and obstructive sleep apnea syndrome (OSAS). Therefore, [18F] FDG PET scan 
is not specific, but has an added negative predictive value18 to exclude (other types of) 
dementia. The preliminary conclusion was that this adjustments after ‘Dual PET’ 
analysis match the clinical diagnosis. Further analysis of clinical and neuropsychological 
subtypes in this cohort will follow.   
163 
 
Biomarkers to diagnose dementia: 
Biomarkers ideally provide an early stage diagnosis of dementia, enabling the  
differentiation between distinct types of neurodegenerative diseases, while they may 
additionally serve as a marker of disease progression. A correct diagnosis is an 
indispensable starting point for dementia research and future therapies. On the other 
hand, a cure for dementia is still missing. Therefore, to consider the application of 
dementia biomarkers in general practice is an individual choice, and depends on the 
specific needs of the patient and his/her family. In practice, it concerns ‘shared decision 
making’ which implies that patients have the right to either be informed, or remain 
unknown about their diagnosis. Also cost effectiveness is an important issue to consider. 
If future treatment trials start to be effective, the role of dementia biomarkers will 
enhance.  
 
CSF biomarkers to diagnose AD:  
CSF biomarkers for AD (low levels of Aβ with high levels of t-tau and p-tau) have high 
sensitivity and specificity compared with cognitively normal individuals19 and are 
embedded in guidelines and clinical criteria of AD20. CSF analysis is relatively 
inexpensive and can be performed in a broad clinical setting and is therefore a preferred 
tool for work up in AD. CSF Aβ42 has a robust correlation with pathology and is an early 
marker of AD21. CSF T-Tau and P-Tau are also increased in AD, but not in several other 
tauopathies22. A high CSF Tau concentration correlates with rapid disease progression23. 
Although, in meta-analysis, CSF biomarkers have not yet reached the required validation 
level to be routinely applied in the clinic24. One of the reasons is that there is substantial 
overlap in abnormal CSF AD markers in several other dementia syndromes25. In real-life 
clinical setting, ‘pure’ etiologies among dementia syndromes are relatively rare and AD 
neuropathology is found in several other neurodegenerative diseases26. CSF biomarkers 
of AD can also be abnormal in cognitively unimpaired individuals27 and in prodromal 
stage of disease28.  As described in chapter 3, the CSF AD biomarker profile raises with 
older age29,30 and is also found in DLB (47%), CBD (38%),  FTD (30%) and VaD (30%). 
Meanwhile,  an evolution has taken place in  neuropathological criteria of dementia 
syndromes to clinicobiological entities and in vivo biomarkers, reflecting the disease-
specific pathophysiological processes26. The NIA-AA working group recently defined AD 
biomarkers for diagnostic research criteria and therapeutic trials, grouped into amyloid-
β deposition, tau pathology and neurodegeneration in the ‘A/T/N classification’3.   
According to amyloid biomarkers: The sensitivity and specificity of CSF Aβ42 is overall 
lower than  amyloid PET24. The concordance of amyloid CSF and amyloid PET markers 
are 60%31 to 80%32, although a more specific ratio of CSF Aβ42/Aβ40 can partly correct 
for  disconcordance33,34. In chapter 8 we assembled 14 AD patients which underwent 
both PIB PET and CSF examination and found a concordance of 54% in [11C]PIB- positive 
subjects and 93% in [11C]PIB-PET negative subjects. If CSF results are doubtful, 
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conflicting or ‘borderline’35, there is an additional value of amyloid PET scan of 35%36. In 
case that  lumbar puncture is not applicable, as it may be refused, not be successful or 
not possible because of risk factors, PET biomarkers may be appropriate. 
 
[18F]FDG PET biomarkers to diagnose different types of dementia: 
[18F]FDG PET brain scan is commonly used in general practice as a topographic marker 
of synaptic dysfunction and is related to neurodegenerative diseases and dementias9. 
Specific metabolic patterns of disease provide a deeper insight into the interplay 
between topography of neurodegeneration and clinical presentation. How [18F]FDG PET 
scan can lead to new insights in mechanisms underlying the topography of  dysfunction 
is shown by the phenomenon of crossed cerebellar diaschisis (CCD) in AD as we 
described in Chapter 7. Pathophysiological mechanism of reduced glucose metabolism 
and [18F]FDG PET hypometabolism correlates with the bloodflow, and may be reversible 
or reflect morphologic change. This strong positive correlation in regional cerebral 
bloodflow and decreased metabolism is also demonstrated in the dual (FDG and PiB 
PET)-tracer study described in Chapter 6. As shown in the preliminary results of the 
‘Dual PET ‘study (Chapter 8): [18F]FDG PET scan can be assessed in the work up, if more 
than one class of dementia is possible to diagnose or when an atypical AD variant is 
suspected. [18F]FDG PET  is the main tool to ascertain atypical AD variants such as PPA 
or PCA36 and improves the differentiation of FTD37 and DLB38. Combined with optimized 
semi-quantitative multivariate approaches such as SSM PCA, [18F]FDG PET can be an 
even more effective tool to support diagnosis in a quantitative fashion. [18F]FDG PET 
scan has a high negative predictive value and a normal scan rules out a 
neurodegenerative disease. For example, in depressed patients an underlying 
neurodegenerative disease may be suspected. In identifying prodromal AD in MCI 
patients, the [18F]FDG PET scan has a similar accuracy39 and is therefore an alternative 
to CSF biomarkers, especially  in older age- with decreased CSF specificity. [18F]FDG PET 
scan may function as a non-specific progression marker of neurodegenerative disease40 
and can therefore also be used as a surrogate outcome measure in clinical trials. A 
limitation of [18F]FDG PET is the lack of specificity in a heterogeneous disease spectrum 
and in mixed dementias and specific neuropathological markers may then be needed.     
 
The role of amyloid PET in clinical practice: 
Amyloid PET is a specific biomarker with a sensitivity  around 95%41, and is therefore 
currently the best tool to rule out AD diagnosis24. The [11C]-PiB PET ligand is capable to 
trace insoluble amyloid in the brain42 but can also be positive in other diseases, such as 
cerebral amyloid angiopathy in patients without dementia43. In clinical practice, amyloid 
PET is employed in case of an unclear diagnosis to (i) rule out or confirm diagnosis of 
AD; (ii) gain support for an atypical presentation with AD CSF profile, or (iii) further 
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evaluate the clinical suspicion of AD in case of negative or unclear CSF results. Also, 
early-stage 11C-PIB uptake may function as a surrogate for 18F-FDG PET, providing an 
index for neuronal function44. The use  of amyloid PET is still very limited in Europe and 
the United States, because the costs are  not reimbursed by the majority of health 
providers. The Alzheimer Biomarker in Daily Practice study is a clinical study to assess 
the diagnostic value of amyloid PET scan in clinical practise45. The ‘Dual PET’ study 
extends on this by investigating how the different PET modalities, increase the clinical 
accuracy. Future analysis of the ‘Dual PET’ study data, including multivariate analysis of 
multiple PET tracers, will focus on the correlation between clinical symptoms, amyloid 
accumulation and neurodegeneration as revealed by regionally impaired 18F-FDG 
uptake. In this, particularly (lateralized) dementia cases may provide further insight in 
underlying disease mechanism.   
 
Future biomarkers for dementia: 
Several future promising biomarkers for the differential diagnosis of dementia have 
become available, of which particularly the development of Tau tracers for PET (such as 
THK5317, THK5351, AV-1451 and PBB3) raise high expectations. To assess their 
usefulness as an early biomarker of the underlying pathology, there is still work to be 
done in order to characterize the binding properties for the variety and complexity of 
the various types of tau deposits in different diseases46,47. New candidate biomarkers for 
AD or other dementias are still under investigation, but sensitivity and specificity 
analysis are not yet applicable for clinical practice6. Specific α-Synucleine biomarkers to 
diagnose Parkinsonian syndromes and DLB are still an unmet need.  Novel ultrasensitive 
immunoassays and mass spectrometry methods are being investigated for future clinical 
practice48. Recent technical development of serologic amyloid biomarkers may have 
potential in the enrichment of AD therapeutic trials. Serologic biomarker ‘Neurofilament 
light’ is a  general marker of neurodegeneration and could be used as a marker of 
progression49. Also multivariate analysis of large sets of serum proteins can be expected 
to achieve a high level of accuracy to predict AD diagnosis50,51.  
 
From biomarkers to clinical and therapeutic trials: 
The majority of biomarkers used in therapeutic trials are based on the ‘amyloid cascade’ 
hypothesis, i.e. the imbalance between production and clearance of the Aβ protein52, 
which leads to toxic deposits of extracellular amyloid plaques53, 54 and aggregates of 
intracellular neurofibrillary tangles4, 55, causing widespread neurodegeneration56. In our 
center we are currently involved in a phase -1 clinical trial, based on RIPK1 as the 
therapeutic target57 to reduce amyloid burden, inflammatory cytokines and memory 
deficits57. Another recently initiated phase 1 trial is a promising therapeutic approach 
for primary and secondary tauopathies58 employing  an antisense oligonucleotide, 
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developed to reduce Tau expression mRNA. Future drug design methods will potentially 
focus on multi-target pharmacological treatment of AD59. However, also other concepts 
concerning complex and multifactorial disease mechanism in dementia may generate 
hypotheses that lead to pioneering research and therapeutic trials. In this respect, the 
notion that the blood-brain barrier (BBB) is a endothelial protecting membrane to 
neurotoxic components and pathogens60 ,with the consequence that BBB dysfunction 
leads to neurodegeneration, is one of such hypotheses. Targeting the BBB dysfunction 
forms the basis for developing new dementia therapies61. In our research group, 
molecular PET tracers, as (R)-[11C]verapamil, are developed to quantify the efflux 
function of P-glycoprotein, an ABC transporter of the BBB and new PET probes are 
focused on improved characteristics62. Another hypothesis to target disease modifying 
strategies of neurodegenerative diseases, is the focus on noradrenergic loss of Locus 
Coeruleus (LC) projection neurons, mediating attention, memory and arousal63. In our 
center we apply [11C] Methylreboxetine (MRB)64, a selective  PET imaging biomarker, to 
measure noradrenaline transporter (NET) availability in LC projection neurons in 
neurodegenerative disorders (AD, DLB and PD). Another important hypothesis of 
neurodegenerative mechanism of diseases is based on the cell's protein degradation of 
the ubiquitin proteasome system (UPS) causing misfolded proteins, and future 
treatment targets are directed to this proteasome65.  
 
To conclude, biomarkers for dementia are important in clinical practice as well as 
research to diagnose and stage AD and other types of dementia. Combining high 
standard clinical practice and clinical research will hopefully lead to the future therapies 
for dementia.    
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